

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6254832

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Ulrike Werthmann	08/06/2020
Gerd-Michael Maier	08/03/2020
Bodo Betzemeier	07/29/2020
Otmar Schaaf	06/29/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	XYNOMIC PHARMACEUTICALS, INC.
<b>Street Address:</b>	3500 SOUTH DUPONT HIGHWAY, SUITE SS101
<b>City:</b>	DOVER
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	19901
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16759187
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	+1 (617) 368-2163
<b>Email:</b>	APSI@fr.com
<b>Correspondent Name:</b>	MEGHANA GUPTA
<b>Address Line 1:</b>	FISH & RICHARDSON P.C.
<b>Address Line 2:</b>	P.O.BOX 1022
<b>Address Line 4:</b>	MINNEAPOLIS, MINNESOTA 55440-1022
<b>ATTORNEY DOCKET NUMBER:</b>	44779-0004US1
<b>NAME OF SUBMITTER:</b>	LAUREN COLICCHIO
<b>SIGNATURE:</b>	/Lauren Colicchio/
<b>DATE SIGNED:</b>	08/18/2020
<b>Total Attachments: 5</b>	
source=44779-0004US1 Assignment#page1.tif	
source=44779-0004US1 Assignment#page2.tif	

source=44779-0004US1 Assignment#page3.tif

source=44779-0004US1 Assignment#page4.tif

source=44779-0004US1 Assignment#page5.tif

ASSIGNMENT

For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, ULRIKE WERTHMANN, GERD-MICHAEL MAIER, BODO BETZEMEIER, and OTMAR SCHAAF, each individually assigns to XYNOMIC PHARMACEUTICALS, INC., a corporation formed under the laws of Wyoming and having a principal place of business at 3500 South DuPont Highway, Suite 55101, Dover, DE 19901, and its successors, transferees, and assignees (collectively the "Assignee"), all of our individual and joint right, title, and interest throughout the world in the invention(s) (the "Subject Matter") described in a patent application that names us as inventors, is titled "CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR," and was filed in the United States Patent and Trademark Office on April 24, 2020, as application 16/759,187 (the "Application").

This Assignment assigns, in addition to the Subject Matter of the Application, (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.


We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee's name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.

We will communicate to the Assignee (or, at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter; will execute and provide all oaths and


declarations, statements, testimony, assignments, powers of attorney, applications, and documents; and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

To the extent any portion of the rights assigned by this assignment have previously been assigned to the assignee or its predecessor in interest, this assignment is a confirmation of previous assignment.

  
Ulrike Werthmann

Date: 08/06/2020

Witnessed by:

Signature: 


Date: 08/06/2020

Print Name: Nicole BORNER

  
Gerd-Michael Maier


Date: 08/01/2020

Witnessed by:

Signature: 

Date: 08/03/2020

Print Name: Nick CORNER

  
Bodo Betzemeier

Date: July 23, 2020

Witnessed by:

Signature: 

Date: 07/23/2020

Print Name: Nicole BORNER

Otmar Schaaf  
Otmar Schaaf

Date: 23-06-2020

Witnessed by:

Signature: Theresa Mayer

Date: 23-06-2020

Print Name: THERESA MAYER

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: XYNOMIC PHARMACEUTICALS, INC.

Signature: Yinglin Xu

Date: August 18, 2020

Name: Yinglin Mark Xu

Title: Chairman and Chief Executive Officer

24013330.doc